- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03712813
Effect of Low Intensity Vibration (LIV) on Aromatase Inhibitor- Induced Musculoskeletal Dysfunction in Early Stage Breast Cancer Survivors
Study Overview
Detailed Description
This is a randomized phase II, two arm, single-center study designed to compare the effect of LIV versus wait-list control on the clinical parameter of energetic capacity, or power generation, in patients with early stage breast cancer receiving aromatase inhibitor therapy over a 12-month period. The primary endpoint is the 12-month change in energetic capacity since baseline.
Primary Objective To compare the effect of LIV delivered for 10 minutes twice daily for 12 months on skeletal muscle function, in terms of energetic capacity measured by power generation on a stationary bicycle, among patients with early stage breast cancer planned to initiate aromatase inhibitor therapy who do not currently participate in regular exercise, compared to a wait- listed control
Secondary Objectives
- To compare the effect of LIV versus wait-listed control upon muscle contractile properties including peak power, fatigue resistance, and recovery, measured by isokinetic knee extension
- To compare the effect of LIV versus wait- listed control upon body composition (lean mass, total adiposity) measured by DXA scan
- To compare the effect of LIV versus wait- listed control upon bone mineral density (T score) measured by DXA scan
- To compare the effect of LIV versus wait- listed control upon muscle adipose infiltration measured by muscle density on peripheral quantitative CT imaging of the proximal and distal tibia and radius
- To compare the effect of LIV versus wait-listed control on trabecular and cortical volumetric bone mineral density by high resolution peripheral quantitative CT of the distal and diaphyseal tibia and radius
- To compare the effect of LIV versus wait- listed control on serologic markers of bone turnover, including TGF-beta and NTX
- To compare the effect of LIV versus wait- listed controls upon patient reported outcome measures of fatigue (measured by the Basic Fatigue Inventory), muscle ache, and joint pain (measured by PRO-CTCAE)
- To describe the feasibility of LIV in this patient population, defined by patient compliance and follow up with the intervention
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Jackson Richey
- Phone Number: 317-274-0922
- Email: jaerich@iupui.edu
Study Contact Backup
- Name: Tarah Ballinger, MD
- Email: tarab@iu.edu
Study Locations
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Recruiting
- Indiana University Melvin & Bren Simon Cancer Center
-
Contact:
- Jackson Richey
- Phone Number: 317-274-0922
- Email: jaerich@iupui.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥ 18 years
Diagnosis of DCIS or stage I, II, or III breast cancer 3 Planned to initiate an AI
- Post- menopausal defined as ≥ 60 years of age, prior bilateral oophorectomy, or age over 50 and absence of any menstrual periods in the last 12 months, or FSH and estradiol in the menopausal range
- Premenopausal patients receiving chemical ovarian suppression are allowed
- Prior aromatase inhibitor use (if this is a second primary, for example) is allowed as long as it has been more than 12 months
- Prior tamoxifen is allowed if switching to an aromatase inhibitor, as long as it has been 28 days between last tamoxifen dose and the baseline procedures (per the half-life of tamoxifen)
4. Completion of all primary therapy for breast cancer, including surgery, radiation, and chemotherapy. Patients must be ≥ 21 days from chemotherapy completion and ≥14 days from radiation completion. Ongoing HER2 targeted therapy with trastuzumab or pertuzumab, or TDM1 is allowed. Neratinib, immunotherapy, or CDK4/6 inhibitor therapy is not allowed.
5. Baseline T score > - 2.5 on DXA 6. Body weight less than 275 lbs., as dictated by the weight limit for the LIV platforms 7. ECOG performance status of 0-2 at the time of study enrollment 8. Informed consent and authorization of the release of health information must be obtained according to institutional guidelines 9. Physically able to stand unassisted for 10 minutes at a time 10. Currently not participating in regular exercise (defined as less than 90 minutes of moderate to vigorous exercise per week measured by the RPAQ questionnaire)
Exclusion Criteria:
- Unwilling to co-enroll onto the companion FIT core study (IRB study #1707550885)
Diagnosis of other disorder affecting bone function or turnover, such as Paget's disease, renal osteodystrophy, parathyroid disorders, vitamin D deficiency/osteomalacia, chronic renal disease (Cr > 1.4)
a. Vitamin D will be checked during screening. Patients with Vit D < 20 can be enrolled if supplementation is initiated per the treating physician.
- Prior history of non-traumatic, fragility bone fracture
- Any muscle or neuromuscular disorder affecting muscle function, such as muscular dystrophy, myositis, or amyotrophic lateral sclerosis
- Use of bisphosphonates or denosumab within the prior 12 months
- History of retinal detachment
- Current or planned pacemaker
- Current or planned cochlear implant
- Any condition precluding power protocol participation (i.e. riding a stationary bicycle), including: NYHA class III or IV congestive heart failure, uncontrolled angina, myocardial infarction in the prior 12 months, orthopedic surgery in the previous 6 months or plans for orthopedic surgery during the study period, chronic uncontrolled pulmonary conditions such as uncontrolled asthma (symptoms > 2 days/week) or dyspnea requiring oxygen, symptomatic peripheral vascular disease, or any other comorbidity that would interfere with the ability to complete and comply with the protocol in the opinion of the investigator
Metastatic breast cancer
a. History of prior treated malignancies, other than breast cancer, that are now stable, are in remission, and do not require active therapy, are acceptable.
- Patients requiring chronic anticoagulation are excluded from participation in the optional muscle biopsy collection.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Macrodyne LivMD plate
|
Synchronous (applied to both feet) low intensity vibration for 10 minutes, twice daily for 12 months.
|
No Intervention: Wait-Listed Control
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean change in energetic capacity measured by peak power generation on a stationary bicycle
Time Frame: Baseline, 6 months, and 12 months
|
Peak power will be measured using the Power Protocol-B
|
Baseline, 6 months, and 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in muscle contractile properties including peak power, fatigue resistance, and time to recovery measured by isokinetic knee extension
Time Frame: Baseline, 6 months, and 12 months
|
A Biodex 4 system will be used to measure each subject's muscle contractile properties
|
Baseline, 6 months, and 12 months
|
Change in lean body mass
Time Frame: Baseline, 6 months, and 12 months
|
Lean mass, total adiposity measured by DXA scan
|
Baseline, 6 months, and 12 months
|
Change in bone mineral density of the lumbar spine by T score
Time Frame: Baseline, 6 months, and 12 months
|
Bone mineral density (T score) measured by DXA scan
|
Baseline, 6 months, and 12 months
|
Change in trabecular and cortical volumetric bone mineral density
Time Frame: Baseline and 12 months
|
By high resolution peripheral quantitative CT of the distal and diaphyseal tibia and radius
|
Baseline and 12 months
|
Change in serologic bone markers of bone turnover (TGF-beta and NTX) by quantitative measurements using ELISA
Time Frame: Baseline and 12 months
|
TGF-beta and NTX by quantitative measurements using ELISA
|
Baseline and 12 months
|
Patient reported fatigue measured by the Basic Fatigue Inventory score
Time Frame: Baseline, 6 months, and 12 months
|
Average of all 9 items ranging in a score of 0-10 (total possible score of 11) scores range from 1( no fatigue/does not interfere) to 10 (as bad as you can imagine/completely interferes)
|
Baseline, 6 months, and 12 months
|
Patient reported aching muscles and joint pain measured by NCI Patient Reported Outcomes-Common Terminology Criteria for Adverse Events score
Time Frame: Baseline, 6 months, and 12 months
|
Average of 2 scale items for aching muscles and joint pain on a 5-point Likert scale (ranging in severity) with a total possible score of 5 (i.e.
very severe/ almost constantly)
|
Baseline, 6 months, and 12 months
|
Feasibility of low intensity vibration defined by patient compliance
Time Frame: Once monthly from Baseline to 12 months
|
Patients will be asked by the study nurse how they are doing with their LIV therapy
|
Once monthly from Baseline to 12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Tarah Ballinger, MD, Indiana University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IUSCC-0680
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
Clinical Trials on Macrodyne LivMD plate
-
University College, LondonUnknownLeg Length Discrepancy | Leg Length DifferenceUnited Kingdom
-
Clinica Universidad de Navarra, Universidad de...University of Bristol; Consorcio Centro de Investigación Biomédica en Red,... and other collaboratorsCompleted
-
Boston Medical CenterCompletedAnkle InjuriesUnited States, Canada
-
United States Army Institute of Surgical ResearchWilliam Beaumont Army Medical CenterUnknown
-
Isfahan University of Medical SciencesUnknownTibial FractureIran, Islamic Republic of
-
Hospital San Carlos, MadridActive, not recruiting
-
Oslo University HospitalActive, not recruitingDistal Radius FractureNorway
-
Hebei Medical University Third HospitalUnknownFracture of Posterior Wall of AcetabulumChina
-
Sohag UniversityCompleted
-
University of BathRoyal Devon and Exeter NHS Foundation TrustCompleted